BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12101279)

  • 1. Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine.
    Ludwig A; Schiemann F; Mentlein R; Lindner B; Brandt E
    J Leukoc Biol; 2002 Jul; 72(1):183-91. PubMed ID: 12101279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties.
    Proost P; Schutyser E; Menten P; Struyf S; Wuyts A; Opdenakker G; Detheux M; Parmentier M; Durinx C; Lambeir AM; Neyts J; Liekens S; Maudgal PC; Billiau A; Van Damme J
    Blood; 2001 Dec; 98(13):3554-61. PubMed ID: 11739156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. I-TAC/CXCL11 is a natural antagonist for CCR5.
    Petkovic V; Moghini C; Paoletti S; Uguccioni M; Gerber B
    J Leukoc Biol; 2004 Sep; 76(3):701-8. PubMed ID: 15178708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3.
    Struyf S; Proost P; Schols D; De Clercq E; Opdenakker G; Lenaerts JP; Detheux M; Parmentier M; De Meester I; Scharpé S; Van Damme J
    J Immunol; 1999 Apr; 162(8):4903-9. PubMed ID: 10202035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11.
    Xanthou G; Duchesnes CE; Williams TJ; Pease JE
    Eur J Immunol; 2003 Aug; 33(8):2241-50. PubMed ID: 12884299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma.
    Suyama T; Furuya M; Nishiyama M; Kasuya Y; Kimura S; Ichikawa T; Ueda T; Nikaido T; Ito H; Ishikura H
    Cancer; 2005 Jan; 103(2):258-67. PubMed ID: 15578685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies.
    Proost P; Struyf S; Loos T; Gouwy M; Schutyser E; Conings R; Ronsse I; Parmentier M; Grillet B; Opdenakker G; Balzarini J; Van Damme J
    Arthritis Res Ther; 2006; 8(4):R107. PubMed ID: 16846531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV.
    Van Coillie E; Proost P; Van Aelst I; Struyf S; Polfliet M; De Meester I; Harvey DJ; Van Damme J; Opdenakker G
    Biochemistry; 1998 Sep; 37(36):12672-80. PubMed ID: 9730840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11).
    Sauty A; Colvin RA; Wagner L; Rochat S; Spertini F; Luster AD
    J Immunol; 2001 Dec; 167(12):7084-93. PubMed ID: 11739530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection.
    Meyer M; Hensbergen PJ; van der Raaij-Helmer EM; Brandacher G; Margreiter R; Heufler C; Koch F; Narumi S; Werner ER; Colvin R; Luster AD; Tensen CP; Werner-Felmayer G
    Eur J Immunol; 2001 Aug; 31(8):2521-7. PubMed ID: 11500837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of CXCR3 receptor agonists in combinatorial small-molecule libraries.
    Stroke IL; Cole AG; Simhadri S; Brescia MR; Desai M; Zhang JJ; Merritt JR; Appell KC; Henderson I; Webb ML
    Biochem Biophys Res Commun; 2006 Oct; 349(1):221-8. PubMed ID: 16930533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivo.
    Stanford MM; Issekutz TB
    J Leukoc Biol; 2003 Nov; 74(5):791-9. PubMed ID: 12960247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3.
    Cole KE; Strick CA; Paradis TJ; Ogborne KT; Loetscher M; Gladue RP; Lin W; Boyd JG; Moser B; Wood DE; Sahagan BG; Neote K
    J Exp Med; 1998 Jun; 187(12):2009-21. PubMed ID: 9625760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and initial evaluation of 4-N-aryl-[1,4]diazepane ureas as potent CXCR3 antagonists.
    Cole AG; Stroke IL; Brescia MR; Simhadri S; Zhang JJ; Hussain Z; Snider M; Haskell C; Ribeiro S; Appell KC; Henderson I; Webb ML
    Bioorg Med Chem Lett; 2006 Jan; 16(1):200-3. PubMed ID: 16213722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific and irreversible cyclopeptide inhibitors of dipeptidyl peptidase IV activity of the T-cell activation antigen CD26.
    Nguyen C; Blanco J; Mazaleyrat JP; Krust B; Callebaut C; Jacotot E; Hovanessian AG; Wakselman M
    J Med Chem; 1998 Jun; 41(12):2100-10. PubMed ID: 9622551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist.
    Heise CE; Pahuja A; Hudson SC; Mistry MS; Putnam AL; Gross MM; Gottlieb PA; Wade WS; Kiankarimi M; Schwarz D; Crowe P; Zlotnik A; Alleva DG
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1263-71. PubMed ID: 15761110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids.
    Proost P; Verpoest S; Van de Borne K; Schutyser E; Struyf S; Put W; Ronsse I; Grillet B; Opdenakker G; Van Damme J
    J Leukoc Biol; 2004 May; 75(5):777-84. PubMed ID: 14996826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation.
    Helbig KJ; Ruszkiewicz A; Semendric L; Harley HA; McColl SR; Beard MR
    Hepatology; 2004 May; 39(5):1220-9. PubMed ID: 15122750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis.
    Okamoto Y; Folco EJ; Minami M; Wara AK; Feinberg MW; Sukhova GK; Colvin RA; Kihara S; Funahashi T; Luster AD; Libby P
    Circ Res; 2008 Feb; 102(2):218-25. PubMed ID: 17991878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycosaminoglycans Regulate CXCR3 Ligands at Distinct Levels: Protection against Processing by Dipeptidyl Peptidase IV/CD26 and Interference with Receptor Signaling.
    Metzemaekers M; Mortier A; Janssens R; Boff D; Vanbrabant L; Lamoen N; Van Damme J; Teixeira MM; De Meester I; Amaral FA; Proost P
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28703769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.